Nasus Pharma (NSRX) Non-Current Assets (2024 - 2025)
Nasus Pharma's (NSRX) quarterly Non-Current Assets came in at $149000.0 in Q4 2025, down 42.69% YoY from $260000.0 in Q4 2024, and down 57.18% on a QoQ basis from $348000.0 in Q2 2025.
Nasus Pharma (NSRX) Non-Current Assets (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has 2 years of Non-Current Assets data on file, last reported at $149000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Nasus Pharma | 30.76 Mn | 30.76 Mn | - | 149,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 149,000.00 |
| Jun 30, 2025 | 348,000.00 |
| Dec 31, 2024 | 260,000.00 |